Q3 EPS Estimate for Unicycive Therapeutics Raised by Analyst

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Stock analysts at Noble Financial raised their Q3 2026 earnings estimates for shares of Unicycive Therapeutics in a research note issued on Thursday, August 13th. Noble Financial analyst R. Leboyer now expects that the company will earn ($0.23) per share for the quarter, up from their prior estimate of ($0.35). The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($1.17) per share. Noble Financial also issued estimates for Unicycive Therapeutics’ Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($0.62) EPS, Q1 2027 earnings at $0.64 EPS and FY2027 earnings at $3.70 EPS.

Several other equities research analysts have also recently issued reports on UNCY. Wall Street Zen raised shares of Unicycive Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Benchmark decreased their target price on Unicycive Therapeutics from $18.00 to $13.00 and set a “speculative buy” rating for the company in a research report on Wednesday, July 1st. HC Wainwright decreased their target price on shares of Unicycive Therapeutics from $22.00 to $15.00 and set a “buy” rating for the company in a research note on Tuesday, June 30th. Guggenheim restated a “buy” rating and set a $25.00 price objective (down from $37.00) on shares of Unicycive Therapeutics in a research note on Thursday, August 13th. Finally, Weiss Ratings raised shares of Unicycive Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, June 9th. Five research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $18.25.

Unicycive Therapeutics Stock Up 1.1%

UNCY stock opened at $5.63 on Monday. The stock’s fifty day simple moving average is $5.88 and its 200-day simple moving average is $6.62. Unicycive Therapeutics has a 52-week low of $3.71 and a 52-week high of $8.74. The stock has a market capitalization of $156.82 million, a price-to-earnings ratio of -3.22 and a beta of 1.79.

Unicycive Therapeutics (NASDAQ:UNCY) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.41.

Institutional Trading of Unicycive Therapeutics

Large investors have recently added to or reduced their stakes in the business. Millennium Management LLC acquired a new position in shares of Unicycive Therapeutics during the fourth quarter valued at $5,856,000. Vivo Capital LLC raised its position in shares of Unicycive Therapeutics by 57.4% during the 3rd quarter. Vivo Capital LLC now owns 1,789,916 shares of the company’s stock worth $7,804,000 after buying an additional 652,901 shares in the last quarter. Cantor Fitzgerald L. P. bought a new stake in shares of Unicycive Therapeutics during the 4th quarter worth about $1,154,000. Dimensional Fund Advisors LP bought a new position in shares of Unicycive Therapeutics in the first quarter valued at approximately $940,000. Finally, Squarepoint Ops LLC bought a new position in shares of Unicycive Therapeutics in the third quarter valued at approximately $512,000. 40.42% of the stock is currently owned by institutional investors and hedge funds.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.